BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35157496)

  • 1. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    Advani AS; Moseley A; O'Dwyer KM; Wood BL; Fang M; Wieduwilt MJ; Aldoss I; Park JH; Klisovic RB; Baer MR; Stock W; Bhave RR; Othus M; Harvey RC; Willman CL; Litzow MR; Stone RM; Sharon E; Erba HP
    J Clin Oncol; 2022 May; 40(14):1574-1582. PubMed ID: 35157496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
    Jabbour E; Short NJ; Jain N; Thompson PA; Kadia TM; Ferrajoli A; Huang X; Yilmaz M; Alvarado Y; Patel KP; Garcia-Manero G; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
    Lancet Haematol; 2022 Dec; 9(12):e878-e885. PubMed ID: 36279879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
    Jabbour E; Short NJ; Senapati J; Jain N; Huang X; Daver N; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Montalban Bravo G; Sasaki K; Kadia TM; Khoury J; Wang SA; Haddad FG; Jacob J; Garris R; Ravandi F; Kantarjian HM
    Lancet Haematol; 2023 Jun; 10(6):e433-e444. PubMed ID: 37187201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
    Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
    Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
    Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
    Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
    Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
    N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
    Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
    Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
    Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
    Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study.
    Boissel N; Chiaretti S; Papayannidis C; Ribera JM; Bassan R; Sokolov AN; Alam N; Brescianini A; Pezzani I; Kreuzbauer G; Zugmaier G; Foà R; Rambaldi A
    Blood Cancer J; 2023 Jan; 13(1):2. PubMed ID: 36599847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
    Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
    Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.